Highlights Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.66 ^USD	+9.21%		+8.50%	+88.64%

Apr. 29	Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	CI
Apr. 15	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	Apr. 29	CI
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	Apr. 15	CI
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	Apr. 09	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	Mar. 19	CI
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	Feb. 22	CI
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial	Feb. 07	CI
Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million.	Dec. 30	CI
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial	Nov. 20	CI
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.	Nov. 13	CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	23-10-30	CI
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.	23-08-14	CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Atossa Therapeutics Gets Regulatory Approval to Conduct Mid-Stage Breast Cancer Therapy in Canada	23-07-20	MT
Atossa Therapeutics Regains Compliance With Nasdaq Listing Rule	23-07-14	MT
Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial	23-07-10	CI
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial	23-06-28	CI
Atossa Therapeutics Board Approves $10 Million Stock Buyback Program	23-06-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Highlights

Filters